Long-lasting changes in synaptic strength are thought to play a pivotal role in activity-dependent plasticity and memory. There is ample evidence indicating that in hippocampal long-term potentiation (LTP) the synthesis of new proteins is crucial for enduring changes. However, whether protein degradation also plays a role in this process has only recently begun to receive attention. Here, we examine the effects of blocking protein degradation on LTP. We show that pharmacological inhibition of proteasome-dependent protein degradation, just like inhibition of protein synthesis, disrupts expression of late (L-)LTP. However, when protein degradation and protein synthesis are inhibited at the same time, LTP is restored to control levels, calling into question the commonly held hypothesis that synthesis of new proteins is indispensable for L-LTP. Instead, these findings point to a more facetted model, in which L-LTP is determined by the combined action of synthesis and degradation of plasticity proteins.
Introduction
Synaptic plasticity is a multistep process that relies on a variety of molecular changes at the synapse. These changes include rapid posttranslational modifications of proteins as well as alterations based on the regulation of the availability of proteins and mRNAs. Whereas it is well-documented that long-term changes in synaptic efficacy, such as late-phase LTP (L-LTP), can be blocked by protein synthesis inhibitors (Frey et al., 1988; Huang et al., 1996 , but see also Fonseca et al., 2006) , the role of protein degradation in hippocampal LTP, which was suggested as early as 1984 (Lynch and Baudry, 1984) , is only starting to be revealed. Protein ubiquitination and subsequent proteasome-dependent degradation provide a general mechanism by which proteins are targeted for degradation or transiently sequestered from the available functional pool (Ciechanover, 2005; Hershko, 2005) , allowing the cell to fine-tune protein availability (for reviews in a neurobiological context, see DiAntonio and Hicke, 2004; Bingol and Schuman, 2005; Yi and Ehlers, 2005; and Patrick, 2006) . It has been shown that proteasome inhibition can result in an accumulation of proteins, such as Homer1a and DUNC-13, which are known to be involved in synaptic plasticity (Ageta et al., 2001a (Ageta et al., , 2001b Ehlers, 2003; Speese et al., 2003) . This suggests that proteasomedependent protein degradation has the potential to control the availability of proteins important for synaptic plasticity by counterbalancing protein synthesis, thereby constraining synaptic enhancement.
Therefore, inhibiting protein degradation might be expected to boost synaptic strengthening and its maintenance. This view is supported by a study of long-term facilitation (LTF) in Aplysia, in which chronic proteasome inhibition increased LTF levels observed 24 hr later (Zhao et al., 2003) . However, evidence suggesting the contrary in mammals was provided by a genetic study showing that a mutation in a specific ubiquitin ligase results in impaired LTP and context-dependent learning deficits (Jiang et al., 1998) . Furthermore, it was shown that proteasome inhibitors injected into the CA1 area of the hippocampus cause retrograde amnesia for one-trial inhibitory avoidance learning in rats, suggesting that proper functioning of the ubiquitin-proteasome system is required for hippocampus-dependent memory formation (Lopez-Salon et al., 2001) .
We set out to study directly how acute manipulation of protein turnover and protein degradation affects mammalian synaptic plasticity. For this, we investigated the effects of pharmacological inhibition of protein synthesis and proteasome blockade on LTP induced at Schaffer collateral-CA1 synapses in the acute rat hippocampal slice preparation. We found that lactacystin and epoxomicin, irreversible blockers of the proteasome, specifically diminish the late phase of LTP, similar to the effect of pharmacological blockade of translation. Intriguingly, coapplication of either proteasome inhibitor with blockers of protein synthesis largely restores L-LTP. This suggests that interfering with either protein synthesis or degradation upsets the balance of plasticity proteins, which are upregulated after LTP induction and required for the synaptic changes to endure, while blocking protein turnover altogether leaves L-LTP intact.
Results

Inhibition of Protein Degradation Diminishes the Stability of LTP
To investigate the role of protein degradation for L-LTP, LTP was induced at Schaffer collateral-CA1 synapses in acute hippocampal slices in the presence of lactacystin (10 nM), an irreversible inhibitor of the proteasome (Dick et al., 1996) . While this did not affect early LTP (E-LTP) ( Figure 1A ; filled blue squares, lactacystin: 169% 6 6%, n = 9; filled black circles, control: 167% 6 4%, n = 30; p = 0.80; 50-60 min after tetanus; green triangles denote p values of the difference between lactacystin and control; for details of the analysis see Experimental Procedures), L-LTP was significantly reduced ( Figure 1A ; filled blue squares, lactacystin: 140% 6 5%, n = 9; filled black circles, control: 162% 6 4%, n = 30; p = 0.002; 200-210 min). A separate control pathway ( Figure 1A , open symbols) showed no decrement, indicating that lactacystin application had no effect on basal synaptic transmission. Therefore, the effects of the blockade of protein degradation specifically affected potentiated synapses. To confirm the effect on L-LTP by proteasomal blockade using lactacystin, we also used epoxomicin (10 nM), another inhibitor of proteasome-dependent protein degradation. Application of epoxomicin resulted in a very similar effect: L-LTP was significantly diminished, even more strongly than in the case of lactcystin ( Figure 1B ; filled light blue squares, epoxomicin: 117% 6 6%, n = 7; filled black circles, control: 162% 6 4%, n = 30; p < 0.001; 200-210 min). Again, a second independent control pathway was recorded simultaneously, showing no decrement in basal synaptic transmission (open symbols).
L-LTP Blockade by Protein Synthesis Inhibition Can Be Counteracted by Proteasome Inhibition
Consistent with the literature (Frey et al., 1988; Huang et al., 1996) , we found that the application of anisomycin, a translation inhibitor, blocked L-LTP ( Figure 1C , data in part from Fonseca et al., 2006) . L-LTP values for anisomycin-treated slices (filled orange squares) were significantly lower than for control slices (filled black circles) (128% 6 3%, n = 18; compared with 162% 6 4%, n = 30; p < 0.001; 200-210 min). Similar to the case of lactacystin, no decrement was observed for the separate control pathway, indicating that the effect of protein synthesis blockade is specific to potentiated synapses.
In order to explore the role of protein degradation under conditions when no protein synthesis is possible, we tested the effect of coapplying anisomycin and lactacystin during the induction of LTP. Both drugs were again bath-applied 40 min before and washed out 1 hr after LTP induction ( Figure 2A ). We observed that lactacystin neutralized the effect of anisomycin. L-LTP values for the anisomycin/lactacystin-treated slices (filled green diamonds) were indistinguishable from the controls (filled black circles) (anisomycin/lactacystin: 162% 6 5%, n = 9; control: 162% 6 4%, n = 30; p = 0.95; 200-210 min). Comparison with Figure 1C shows that LTP values for anisomycin/lactacystin-treated slices were indeed significantly higher than for anisomycin alone ( Figure 2A , anisomycin/lactacystin: 162% 6 5%, n = 9; Figure 1C , anisomycin: 128% 6 3%, n = 8; p < 0.001). These data indicate that blockade of protein synthesis does not diminish L-LTP, provided that protein degradation is also inhibited.
To rule out the possibility that this result was due to some particularity of the drugs used, we performed (A) L-LTP was blocked by inhibition of proteasome-dependent protein degradation (10 nM lactacystin). fEPSPs were recorded at a frequency of 0.1 Hz. LTP values for lactacystin-treated slices (filled blue squares) were significantly lower than control values (filled black circles) at the end of the recording (140% 6 5%, n = 9, compared with 162% 6 4%, n = 30; p = 0.002; green triangles denote p values). A second, independent control pathway was recorded simultaneously, showing no decrement in basal synaptic transmission (open symbols). The green triangles denote p values (two-tailed Student's t test; control versus experimental situation) for 10 min data bins (see Experimental Procedures). The insets show individual fEPSP traces for lactacystin (blue) and control (black) conditions at times indicated by the letters. (B) L-LTP was also blocked by epoxomicin (10 nM), an inhibitor of proteasome-dependent protein degradation. LTP values for epoxomicin-treated slices (filled light blue squares) were significantly lower than control values (filled black symbols) at the end of the recording (117% 6 6%, n = 7, compared with 162% 6 4%, n = 30; p < 0.001; green triangles denote p values). A second independent control pathway was recorded simultaneously, showing no decrement in basal synaptic transmission (open symbols). (C) Protein synthesis inhibitors effectively block L-LTP. LTP was induced in the presence of anisomycin (25 mM), a reversible translation blocker. LTP values for anisomycin-treated slices (filled orange squares) were significantly lower than for control slices (filled black circles) at the end of the recording (128% 6 3%, n = 18, compared with 162% 6 4%, n = 30; p < 0.001; green triangles denote p values). A second, independent control pathway was recorded simultaneously, showing no decrement in basal synaptic transmission (open symbols). The data for the anisomycin experiments in this panel were published previously (Fonseca et al., 2006) . Inset scale bars, 1 mV, 10 ms. Error bars = SEM.
the same experiments using emetine, which is known to block L-LTP (Stanton and Sarvey, 1984; Bradshaw et al., 2003) , as the protein synthesis inhibitor instead of anisomycin. We induced LTP in the presence of emetine (25 mM) alone or together with lactacystin (10 nM). Both drugs were bath-applied 40 min before and washed out 1 hr after LTP induction. LTP values for the emetine/lactacystin-treated slices ( Figure 2C , filled purple diamonds; emetine/lactacystin: 142% 6 6%, n = 7) were in this case significantly lower than for controls ( Figure 2C , filled black circles; control: 162% 6 4%, n = 30; p = 0.01) at the end of the recording, but significantly higher than for slices treated only with emetine ( Figure 2C , filled purple diamonds; emetine/lactacystin: 142% 6 6%, n = 7; filled red squares, emetine: 107% 6 9%, n = 6; p = 0.01). Therefore, while the effect was quantitatively reduced with emetine, there was still a qualitative and significant rescue of L-LTP that occurred when protein degradation had been blocked by lactacystin. Finally, to confirm the findings we used another blocker of the proteasome, epoxomicin, and checked whether it could also rescue the effect of anisomycin on L-LTP. Epoxomicin (10 nM) in combination with anisomycin (25 mM) yielded results that mirrored the effects we observed when proteasomal activity was impaired by lactacystin ( Figure 2B ; filled brown diamonds, anisomycin/epoxomicin: 142% 6 13%, n = 7; filled black circles, control: 162% 6 4%, n = 30; p = 0.17).
To make the data more comparable, we also chose a different way to display the data and normalized them on the magnitude of LTP in the respective experiment (Figure 3 ). This way of displaying the data shows clearly that lactacystin, epoxomicin, anisomycin, and emetine have very similar effects of diminishing LTP, whereas the combinations of anisomycin/lactacystin, emetine/lactacystin, and anisomycin/epoxomicin are almost indistinguishable from controls; i.e., the effects of anisomycin/emetine and lactacystin/epoxomicin almost completely compensate each other.
Biochemical Confirmation of Drug Effects
We confirmed that the bath application of 10 nM lactacystin or 10 nM epoxomicin impairs the activity of the proteasome in hippocampal slices. To this end, we performed biochemical experiments determining the expected accumulation of polyubiquitinated proteins following proteasome blockade ( Figure 4A ; see Experimental Procedures for details). In two experiments, a . LTP values in anisomycin/lactacystin-(filled green diamonds) treated slices were not significantly different from those obtained in control experiments (162% 6 5%, n = 9, compared with 162% 6 4%, n = 30; p = 0.95; green triangles denote p values). (B) Concurrent application of anisomycin and epoxomicin rescues L-LTP. When LTP was induced in the presence of anisomycin and epoxomicin (filled brown squares), no decrement was observed at any time throughout the recording time compared to controls (filled black circles), including at the end of the recording (200-210 min) (142% 6 13%, n = 7, compared with 162% 6 4%, n = 30; p = 0.17). (C) Emetine (25 mM) coapplied with lactacystin (10 nM) (purple diamonds) shows an effect similar to the anisomycin/lactacystin experiment (emetine/lactacystin: 142% 6 6%, n = 7, compared with emetine alone: 107% 6 9%, n = 6; p = 0.01). Inset scale bars, 1 mV, 10 ms. Error bars = SEM. Percentage of decay of LTP values was determined by the ratio between 10 min data bins shortly after LTP induction (indicated by [1] in Figure 1A ) and 10 min data bins at the end of the recording (indicated by [2] in Figure 1A 
. Control values were averaged between all control experiments. Proteasome and translation blockers alone all strongly block L-LTP (columns 5-8), whereas concurrent application of both rescues L-LTP (columns 2-4). Error bars = SEM.
small but consistent accumulation of polyubiquitinated protein species in slices incubated with the proteasome inhibitors was observed ( Figure 4A ; normalized pixel values for experiment 1: 148%, lacta; 149%, epox; 99%, ani; 120%, MG132; and 100%, control; normalized pixel values for experiment 2 [data not shown]: 112%, lacta; 132%, epox; and 100%, control). This indicates that proteasome-dependent degradation was indeed impaired when lactacystin or epoxomicin had been applied.
In order to prove conclusively that L-LTP can occur in the absence of the production of new proteins, it is essential to verify that no protein synthesis is occurring under our experimental conditions. To this end, we assayed protein synthesis directly by measuring radioactive amino acid incorporation under the same experimental conditions. Acute hippocampal slices were prepared and treated exactly as they were for the electrophysiological experiments. Anisomycin (25 mM) alone and anisomycin (25 mM) together with lactacystin (10 nM) were bath-applied in the presence of 10 mCi/ml of [
35 S]-methionine. Slices were lysed after 20, 40, and 60 min, and the amino acid incorporation was assessed by autoradiography (see Experimental Procedures).
No [
35 S]-methionine incorporation ( Figure 4B ) was detected, although similar amounts of protein were loaded in the different lanes of the SDS-PAGE gel ( Figure 4C ), demonstrating that translation was effectively blocked under our experimental conditions. Similarly, the anisomycin/lactacystin condition showed no signs of appreciable [ 35 S]-methionine incorporation, ruling out any nonspecific effects of the combination of drugs. These effects were confirmed with a different translational blocker (25 mM emetine; see Figure S1 in the Supplemental Data).
Further Controls
To check whether blocking the proteasome acutely affects basal synaptic transmission in slice hippocampal neurons, we carried out several electrophysiological analyses. We measured input/output curves for control, lactacystin-, and lactacystin/anisomycin-treated slices ( Figure 4D ). After 40 min of bath application of the drugs, field excitatory postsynaptic potential (fEPSP) amplitudes were measured in response to increasingly intense stimulation of the afferents by current injections in steps of 20 mA. No significant differences were obtained for the three conditions tested. We also assessed paired-pulse facilitation, measuring fEPSP responses for 10, 20, 40, 80, and 160 ms interstimulus intervals, which were not affected significantly by lactacystin or anisomycin/lactacystin ( Figure 4E) .
Moreover, we reanalyzed our data by measuring the integral (''area under the curve'') of the fEPSP responses before and after LTP induction in control, lactacystin-, emetine/lactacystin-, and anisomycin/lactacystin-treated slices. Indeed, the integral analysis qualitatively yielded the same results as the slope analysis, indicating that the drug effects are robust (Figures 4F and 4G) . Finally, we performed repeated measures ANOVA on the data set from the slope analysis, which fully confirm our conclusions (see Table S1 in the Supplemental Data).
Discussion
The experiments described above have two major results. First, they show that interfering with the degradation of proteins-just like interfering with their production-strongly diminishes L-LTP. Second, they make the surprising point that protein synthesis is not an absolute requirement for L-LTP. Therefore, models that only consider the effects of protein synthesis for L-LTP need to be amended to include protein degradation.
Even though the observation that proteasome inhibition results in an impairment in L-LTP could at first glance be considered as surprising (but see recent report by Karpova et al., 2006) , there are several studies in the literature that are in line with this finding. Proteasome inhibition was shown to block long-term memory formation in rodents (Lopez-Salon et al., 2001 ) and long-term facilitation in Aplysia (Chain et al., 1995 (Chain et al., , 1999 . Moreover, mice with maternal deficiency due to a mutation in the E6-AP ubiquitin ligase have impaired LTP, providing genetic evidence for the role of ubiquitination in synaptic enhancement (Jiang et al., 1998) . In addition, ubiquitination has been reported to mediate long-term depression (LTD), marking PSD-95 for removal from synaptic sites in response to NMDA receptor activation and low-frequency synaptic stimulation (Colledge et al., 2003) . Furthermore, AMPA-induced AMPA receptor internalization is blocked by brief applications of proteasome inhibitors (Patrick et al., 2003) . Finally, there is evidence that synaptic growth and function at the Drosophila neuromuscular junction depend on proper levels of ubiquitination (DiAntonio et al., 2001 ). These findings point to a key role of proteasome-dependent protein degradation in synaptic plasticity. The possibility that degradation of synaptic proteins might be under activity-dependent control is further supported by recent work from our group showing that the decay of LTP during protein synthesis blockade depends strongly on the level of synaptic activation that the potentiated synapses experience (Fonseca et al., 2006) .
The fact that proper functioning of the proteasome is required for the maintenance of LTP argues against a simple model in which ''positive'' effector proteins alone are upregulated after LTP induction. In this case blocking protein degradation would be expected to enhance LTP. A scenario more consistent with the experiments described above assumes a critical role of ''negative'' effector proteins, which would normally be targeted for degradation after LTP induction, thereby unmasking the action of the positive effector proteins. Figure 5 shows a model that illustrates the effects of blocking protein synthesis and degradation separately or at the same time. In the presence of drugs that block protein synthesis, any production of positive and negative plasticity proteins after LTP induction is prevented, leading to diminished L-LTP levels. Under these conditions the time course of LTP should reflect the shifting balance between the levels of the preexisting pool of positive and negative effector proteins and their degradation. In the presence of lactacystin/epoxomicin, which block protein degradation, the negative effector proteins would not be degraded, leading to a reduction in L-LTP expression. This scenario is along the lines of what has been shown in studies of Aplysia LTF (Hegde et al., 1993 (Hegde et al., , 1997 Chain et al., 1995) , which showed that proteasome-dependent degradation is responsible for the loss of an inhibitory regulatory subunit of the protein kinase A (PKA), which disinhibits LTF. The scenario is also consistent with the rescue effect observed when protein degradation was blocked pharmacologically at the same time as protein synthesis. In this case, the preexisting pool of positive effector proteins would be sufficient to ensure synaptic potentiation. Testing this model further will most likely require knowing the identity of the positive and negative effector proteins in order to manipulate their activity and/or expression levels separately. Interestingly, a recent paper concludes that associative learning in Drosophila triggers a proteasome-mediated release of suppression of gene expression of synaptic proteins that are associated with a stable memory (Ashraf et al., 2006) , raising the possibility that the regulation of the proteasome plays a major and largely unexplored role in shaping neuronal circuits important for learning and memory. Furthermore, it has been shown that growth cone responses in axon guidance (Campbell and Holt, 2001 ) and the plasticity of Aplysia sensory-motor synapses (Zhao et al., 2003) are determined by the balance of protein synthesis and protein degradation.
While our model is certainly an oversimplification of the cell biological dynamics of protein synthesis and degradation, it correctly captures the drug effects on L-LTP we observed.
The outcome of the experiment in which anisomycin/ emetine and lactacystin/epoxomicin were applied simultaneously has important consequences for the current thinking on long-term synaptic plasticity. It is widely believed that the late phase of LTP critically depends on protein synthesis being intact (Huang et al., 1996; Barco et al., 2002; Calixto et al., 2003; Cammalleri et al., 2003 ). This conclusion is based on the fact that translational blockers in a number of different experimental settings inhibited L-LTP while leaving the early component of LTP unaffected. Although this conclusion seems reasonable at first glance, our experiments show that it is not necessarily warranted. Protein synthesis is indeed needed when protein degradation is functional. However, when protein degradation is blocked, the requirement for de novo protein synthesis becomes obsolete, suggesting that synapses are constitutively endowed with the necessary molecular components to support even longer lasting changes in synaptic strength.
Experimental Procedures
Slice Preparation, Electrophysiological Recordings, and Analysis The detailed procedure for acute hippocampal slice preparation and recording of extracellular fEPSPs has been described elsewhere (Fonseca et al., 2004) . Briefly, 400 mm thick brain slices were acutely prepared from male Wistar rats (3 to 4 weeks old). Recordings started after a 20 min resting period in the recording chamber maintained at 32 C. Schaffer collaterals were stimulated with 0.2 ms pulses using monopolar tungsten electrodes. Stimulus intensities were set to evoke 50% of the maximal fEPSP slope and LTP was induced after recording a stable baseline of fEPSPs for 40 min. The test pulse frequency was 0.1 Hz. Two stimulating electrodes were positioned in the stratum radiatum, allowing us to stimulate two independent sets of Schaffer collaterals. For any given drug or drug combination, the experiments were interleaved with control experiments in a blind fashion. After baseline stimulation, one of the pathways was arbitrarily chosen to receive tetanic stimulation of 100 Hz for 1 s. The control pathway was monitored continuously, allowing us to assess the overall health of the slice. Experiments were rejected if the control pathways had decayed more than 30% below baseline. The fraction of rejected experiments was comparable for the various drug and control conditions. Offline data analysis was performed using a customized LabView-program (National Instruments). As a measure of synaptic strength, the initial slope of the evoked fEPSPs was calculated and expressed as a percent change from the baseline mean. Error bars in figures denote SEM values. To test for group differences between LTP values across conditions, a two-tailed Student's t test was used (green triangles indicate p values). To this end, LTP values were averaged into 10 min data bins. In addition, we performed repeated measures ANOVA across the drug conditions; the time windows are detailed in Table S1 .
The effects of the various drug combinations were statistically tested against drug-free control experiments that were carried out in an interleaved and blindfolded way for each of the experimental conditions. For the figures, we pooled all the controls from all the experimental series and show the overall control values for the pooled dataset as well as the associated p values. We verified that the other way of testing the data (comparing control and experiment within each data set) led to the same results (data not shown).
Proteasome and Protein Synthesis Inhibitors
Lactacystin and epoxomicin (Sigma, Munich, Germany) were dissolved in DMSO and diluted down to achieve a final concentration of 10 nM (in 0.01% DMSO). Anisomycin and emetine (Sigma) were dissolved in DMSO and diluted down to achieve a final concentration of 25 mM (in 0.01% DMSO). All drugs were bath-applied for 40 min before and washed out 1 hr after LTP induction. For the control experiments only, DMSO (0.01%) was added to the artificial cerebrospinal fluid (ACSF).
Assessment of Blockade of Protein Synthesis and Degradation
To assess whether emetine and anisomycin, at the concentration used and under the circumstances of our experiments, reliably block protein synthesis (Stanton and Sarvey, 1984; Rosenblum et al., 1993) , we measured the incorporation of [
35 S]-methionine into newly synthesized proteins. Hippocampal slices were prepared following the same procedure as detailed for the electrophysiological experiments. After an hour-long resting phase, slices were transferred to an incubation chamber at 32 C. After an equilibration period of 10 min, anisomycin (25 mM), emetine (25 mM), and anisomycin (25 mM)/lactacystin (10 nM) were bath-applied with 10 mCi/ml of [ 35 S]-methionine (Amersham Biosciences, Munich, Germany). For analysis of translational activity, slices were collected 20, 40, and 60 min after adding the drugs and the radioactive agent and lysed in preheated lysis buffer (125 mM TrisHCl [pH 6.8], 2% SDS, 25% glycerol, 200 mM DTT). DNA was sheared, and lysates were centrifuged at 14,000 r.p.m. for 10 min. Protein concentration was determined using Coomassie Protein Assay Reagent Kit (Pierce, Bonn, Germany). Equal amounts of protein were separated in 10% SDS-PAGE. To assess total protein, gels were stained with Coomassie blue, destained, and scanned. Subsequently, the gels were dried and exposed to the radioactivity screen. Images were scanned and analyzed using FLA-2000 Image analyzer (FujiFilm) and AIDA software (Raytest) .
To analyze proteasome activity, hippocampal slices were incubated with lactacystin (10 nM) and epoxomicin (10 nM) for 2 hr. In addition to the drug-free control, we used MG132 (20 mM), another inhibitor of the proteasome, as a positive control. Subsequently, their lysates were prepared and western blotted against polyubiquitin (monoclonal antibody clone P4D1, Santa Cruz Biotechnology, Santa Cruz, CA). The intensity of each band (averaged over equal areas for all conditions) was normalized by the signal from an antibody against GAPDH (Chemicon, Temecula, CA) to account for differences in gel loading for the various conditions.
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